Loading...
XNAS
CERS
Market cap397mUSD
Dec 05, Last price  
2.07USD
1D
-1.43%
1Q
55.64%
Jan 2017
-52.41%
Name

Cerus Corp

Chart & Performance

D1W1MN
XNAS:CERS chart
P/E
—
P/S
2.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.71%
Rev. gr., 5y
19.28%
Revenues
180m
+15.29%
24,371,00035,580,00011,044,00016,507,00017,982,00023,109,00033,044,00036,695,00039,657,00036,503,00034,223,00037,183,00043,568,00060,908,00074,649,00091,920,000130,859,000162,048,000156,367,000180,270,000
Net income
-21m
L-44.20%
13,064,000-4,779,000-45,304,000-29,181,000-24,135,000-16,911,000-16,982,000-15,917,000-43,337,000-38,566,000-55,868,000-62,906,000-60,585,000-57,564,000-71,244,000-59,857,000-54,376,000-42,825,000-37,489,000-20,918,000
CFO
11m
P
-14,947,000-14,685,000-37,402,000-34,545,000-14,664,000-14,111,000-15,632,000-13,917,000-26,797,000-39,811,000-51,129,000-53,529,000-52,235,000-31,246,000-65,838,000-40,743,000-33,922,000-25,615,000-43,168,00011,359,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
URL
https://www.cerus.com/
IPO date
Jan 31, 1997
Employees
665
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT